Acadian Asset Management LLC boosted its position in Harmony Biosciences by 69.7% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/05/27/mercer-global-advisors-inc-adv-purchases-new-shares-in-harmony-biosciences-holdings-inc-nasdaqhrmy/

According to data from MarketBeat, Ventyx Biosciences has an average rating of “Hold” and a consensus price target of $31.

Source: https://www.dailypolitical.com/2023/12/24/insider-selling-ventyx-biosciences-inc-nasdaqvtyx-insider-sells-37371-36-in-stock.html

Alberta Investment Management Corp raised its holdings in Neurocrine Biosciences by 10.4% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

Analysts at Scotiabank started coverage on shares of Castle Biosciences ( in a research note issued on Wednesday, reports.

Source: https://www.dailypolitical.com/2023/01/04/castle-biosciences-nasdaqcstl-coverage-initiated-at-scotiabank.html

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.

Source: https://www.marketscreener.com/quote/stock/ARCUS-BIOSCIENCES-INC-42096830/news/Gilead-and-Arcus-Announce-Anti-TIGIT-Domvanalimab-Continues-to-Demonstrate-Consistent-Improvement-in-44034075/?utm_medium=RSS&utm_content=20230603

Ark Invest purchased 37,340 shares of Pacific Biosciences of California, a renowned name in the field of genomics through ARKK and ARKG.

Source: https://www.benzinga.com/23/10/35153614/cathie-wood-goes-shopping-for-stock-of-jack-dorseys-block-ark-invest-bolsters-portfolio-with-archer

Artisan Partners Limited Partnership raised its holdings in Avidity Biosciences by 46.5% in the 1st quarter.

Source: https://www.americanbankingnews.com/2023/11/05/raymond-james-associates-has-925000-stock-holdings-in-avidity-biosciences-inc-nasdaqrna.html

As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 2.17 EPS for the current year.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

As a group, sell-side analysts predict that Neurocrine Biosciences will post 2.2 EPS for the current fiscal year.

Source: https://www.etfdailynews.com/2023/09/17/neurocrine-biosciences-nasdaqnbix-earns-overweight-rating-from-cantor-fitzgerald/

Avidity Biosciences is advancing highly intriguing next-generation RNA medicines.

Source: https://seekingalpha.com/article/4596207-avidity-an-interesting-diversification?source=feed_all_articles

Bank of America dropped their target price on Caribou Biosciences from $27.00 to $25.00 in a research note on Friday, March 17th.

Source: https://www.dailypolitical.com/2023/05/31/caribou-biosciences-inc-nasdaqcrbu-sees-large-increase-in-short-interest-2.html

Barclays began coverage on Pacific Biosciences of California in a research note on Wednesday, May 10th.

Source: https://www.etfdailynews.com/2023/08/29/guggenheim-capital-llc-cuts-position-in-pacific-biosciences-of-california-inc-nasdaqpacb/

Barclays PLC increased its stake in shares of Harmony Biosciences by 2.6% in the second quarter.

Source: https://www.etfdailynews.com/2023/10/16/harmony-biosciences-nasdaqhrmy-pt-lowered-to-42-00-at-piper-sandler/

BNP Paribas Arbitrage SNC bought a new position in Aura Biosciences in the 3rd quarter valued at $105,000.

Source: https://www.etfdailynews.com/2023/04/01/aura-biosciences-inc-nasdaqaura-short-interest-update/

Brown Advisory Inc. increased its holdings in Neurocrine Biosciences by 0.5% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/02/25/aviva-plc-sells-3537919-shares-of-neurocrine-biosciences-inc-nasdaqnbix.html

Brown Capital Management LLC raised its holdings in shares of Cytek Biosciences by 24.8% during the 2nd quarter.

Source: https://www.etfdailynews.com/2023/10/28/patrik-jeanmonod-sells-3000-shares-of-cytek-biosciences-inc-nasdaqctkb-stock/

BTIG Research restated a “buy” rating and set a $70.00 price target on shares of Arcus Biosciences in a research note on Wednesday.

Source: https://www.etfdailynews.com/2023/08/26/federated-hermes-inc-buys-2203-shares-of-arcus-biosciences-inc-nysercus-2/

But now, Colossal Biosciences, the firm behind the dodo resurrection, is hoping to restore the thylacine, and aims to have a ‘de-extincted thylacine-ish thing’ within a decade.

Source: https://metro.co.uk/2023/09/30/de-extinction-will-we-ever-bring-animals-back-from-the-dead-19577423/

Cantor Fitzgerald reaffirmed an “overweight” rating and set a $136.00 price objective on shares of Neurocrine Biosciences in a research note on Tuesday.

Source: https://www.etfdailynews.com/2023/08/25/insider-selling-neurocrine-biosciences-inc-nasdaqnbix-cfo-sells-2132-shares-of-stock/

Castle Biosciences, Inc. has a 12 month low of $15.58 and a 12 month high of $47.27.

Source: https://www.americanbankingnews.com/2023/03/11/insider-selling-castle-biosciences-inc-nasdaqcstl-insider-sells-2792-shares-of-stock.html